EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study

Vipul Jairath, Geert D'Haens, Bruce E Sands, Simon Travis, María Chaparro, Laurent Peyrin-Biroulet, Min-Hu Chen, Marla Dubinsky, Marc Ferrante, Stefan Schreiber, Kim McGinnis, Aisha Vadhariya und 6 weitere

Clinical Gastroenterology and Hepatology · 2026-02 · 24 (2) · 463-473.e5

DOI: 10.1016/j.cgh.2025.07.003 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-02. Verfasst von Vipul Jairath und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, University Hospital, London, Ontario, Canada; Division of Epidemiology and Biostatistics, Weste…. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Bowel urgency (BU) is an underrecognized and debilitating symptom of Crohn's disease. Mirikizumab, an interleukin-23p19 inhibitor, is efficacious for BU resolution in ulcerative colitis. We evaluated the efficacy of mirikizumab in achieving early BU response and remission among participants with Crohn's disease enrolled in the phase 3 VIVID-1 study. The associations of disease characteristics with baseline BU and BU resolution were explored. METHODS: Adult participants were randomized to receive mirikizumab or placebo. BU was assessed using the Urgency Numeric Rating Scale (NRS) (range 0-10) at baseline, and every 4 weeks. The proportion of participants with baseline Urgency NRS ≥3 and ≥6 who achieved BU clinically meaningful improvement (CMI) (≥3 change in Urgency NRS) and BU remission (Urgency NRS ≤2) was calculated, and associations of BU CMI and BU remission with clinical outcomes were assessed. RESULTS: At baseline, 94.2% of participants had an Urgency NRS score ≥3. BU positively correlated with the Crohn's Disease Activity Index and abdominal pain. Improvement in BU from baseline was significantly greater in mirikizumab-treated participants as early as week 6 and sustained to week 52 vs patients receiving placebo. Participants treated with mirikizumab achieved significantly higher rates of BU CMI and BU remission at weeks 12 and 52 vs placebo. Mirikizumab-treated participants who achieved BU CMI at week 12 had better clinical and endoscopic outcomes at weeks 12 and 52. CONCLUSIONS: Mirikizumab-treated participants achieved significantly higher rates of BU CMI and remission at weeks 12 and 52, which was associated with better short- and longer-term clinical outcomes. CLINICALTRIALS: gov, Number: NCT03926130.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAntibodies, Monoclonal, HumanizedGastrointestinal AgentsHumansMaleFemaleAdultMiddle AgedTreatment OutcomeYoung AdultDouble-Blind MethodPlacebosInterleukin-23 Subunit p19Remission Induction

Stichwörter der Autor:innen

Bowel UrgencyCrohn’s DiseaseMirikizumabUrgency NRS

Substanzen

Antibodies, Monoclonal, HumanizedPlacebosInterleukin-23 Subunit p19Gastrointestinal Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, University Hospital, London, Ontario, Canada; Division of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. Electronic address: vjairath@u…
  • Inflammatory Bowel Disease Centre, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: g.dhaens@amsterdamumc.nl.
  • Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Kenney Institute, Translational Gastroenterology Unit and Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
  • Department of Gastroenterology, Instituto de Investigación Sanitaria del Hospital de La Princesa, Hospital Universitario de La Princesa, CIBEREHD, Universidad Autónoma de Madrid, Madrid, Spain.
  • Department of Gastroenterology, INFINY Institute, INSERM NGERE, CHRU Nancy, Vandœuvre-lès-Nancy, France; Groupe Hospitalier privé Ambroise Paré - Hartmann, Paris IBD center, Neuilly sur Seine, France; Division of Gastro…

Förderung

  • Eli Lilly and Company

Zitieren

APA

Jairath, V., D'Haens, G., Sands, B. E., Travis, S., Chaparro, M., Peyrin-Biroulet, L., Chen, M. H., Dubinsky, M., Ferrante, M., Schreiber, S., McGinnis, K., Vadhariya, A., Appelmans, S., Lin, Z., Yu, G., Protic, M., Moses, R., & Ghosh, S. (2026). Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study. Clinical Gastroenterology and Hepatology, 24(2), 463-473.e5. https://doi.org/10.1016/j.cgh.2025.07.003

Vancouver

Jairath V, D'Haens G, Sands BE, Travis S, Chaparro M, Peyrin-Biroulet L, et al. Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study. Clinical Gastroenterology and Hepatology. 2026;24(2):463-473.e5. doi:10.1016/j.cgh.2025.07.003

BibTeX
@article{Jairath2026,
  author = {Jairath, Vipul and D'Haens, Geert and Sands, Bruce E and Travis, Simon and Chaparro, María and Peyrin-Biroulet, Laurent and Chen, Min-Hu and Dubinsky, Marla and Ferrante, Marc and Schreiber, Stefan and McGinnis, Kim and Vadhariya, Aisha and Appelmans, Saskia and Lin, Zhantao and Yu, Guanglei and Protic, Marijana and Moses, Richard and Ghosh, Subrata},
  title = {Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {2},
  pages = {463--473.e5},
  doi = {10.1016/j.cgh.2025.07.003}
}
Kostenlos starten →